Senti Biosciences, Inc.

NasdaqCM SNTI

Senti Biosciences, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024

Senti Biosciences, Inc. Gross Profit is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Senti Biosciences, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -11.47 M, a 5.71% change year over year.
Senti Biosciences, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -12.17 M.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqCM: SNTI

Senti Biosciences, Inc.

CEO	Dr. Timothy K. Lu M.D., Ph.D.
IPO Date	May 26, 2021
Location	United States
Headquarters	2 Corporate Drive
Employees	48
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.

Key trends

Past 5 years